July 29, 2014 4:41 AM ET

Pharmaceuticals

Company Overview of Visterra, Inc.

Company Overview

Visterra, Inc. engages in the discovery and development of products for the prevention, treatment, and diagnosis of infectious diseases. The company focuses on seasonal and pandemic influenza. Its products include therapeutic agents for influenza; vaccines for pandemic and seasonal influenza; and a prototype for the first functional influenza diagnostic that identifies the subtype and extent of human transmissibility of various influenza viruses. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Visterra, Inc. in May 2010. The company was founded in 2007 and is based in Cambridge, Massachusetts.

One Kendall Square

Suite B3301

Cambridge, MA 02139

United States

Founded in 2007

Phone:

617-498-1070

Fax:

617-498-1073

Key Executives for Visterra, Inc.

Chief Executive Officer
Age: 55
Founder and Chairman
Age: 51
Founder and Director
Age: 49
Chief Financial Officer and Chief Operating Officer
Age: 53
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Visterra, Inc. Key Developments

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.

Visterra Inc. Acquires Exclusive Patent License for Monoclonal Antibodies Against Dengue Virus from Massachusetts Institute of Technology

Visterra Inc. announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

Visterra, Inc. Announces Management Changes

Visterra, Inc. announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, David Arkowitz has joined the company as Chief Operating Officer and Chief Financial Officer, and Greg Miller will serve as Vice President of Business Development and Strategic Planning. Most recently, Mr. Arkowitz was at Mascoma Corporation, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Prior to joining Mascoma, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals. Most recently, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals since 2010. Prior to that, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals from 2008 to 2010.

Similar Private Companies By Industry

Company Name Region
NorthStar Medical Radioisotopes, LLC United States
InfoQuest Clinical Network, Inc. United States
CaraMedica Pharmaceuticals, Inc. United States
GlaxoSmithKline Consumer Healthcare, L.P. United States
Vitacoat Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Visterra, Inc., please visit www.visterrainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.